CD274 and melanoma: In a study on melanoma patients treated with surgery and dacarbazine, patients with positive PD-L1 on IHC staining had lower median survival time compared with the subgroup with negative or indeterminate PD-L1 status (9.7 months vs. 11.6 months) [17].